Diabetes device reimbursement in the EU-5

Area of Science:

• Health economics and outcomes research
• Medical device market access
• European healthcare policy

Background:

• Reimbursement for innovative diabetes devices in Europe is highly varied and lacks transparency.
• Each European Union (EU) country utilizes distinct mechanisms, pathways, and requirements for device reimbursement.
• This heterogeneity presents significant challenges for manufacturers of novel diabetes technologies.

Purpose of the Study:

• To provide an overview of diabetes device reimbursement in the outpatient setting across the five major European Union markets (EU-5).
• To analyze market categorization (centralized vs. regionalized systems) and its implications for device reimbursement.
• To detail specific requirements and success factors for achieving widespread reimbursement in the EU-5.

Main Methods:

• Categorization of EU-5 markets based on reimbursement decision-making systems (centralized vs. regionalized).
• Analysis of specific requirements for reimbursement, including evidence generation and influencer engagement.
• Exploration of success factors such as clinical, health-economic (cost-effectiveness, budget impact), and pricing strategies.

Main Results:

• European reimbursement systems for diabetes devices are diverse, necessitating country-specific strategies.
• Key success factors include early engagement with key opinion leaders and payers.
• Compelling clinical and health-economic evidence, alongside appropriate pricing, is crucial for securing reimbursement.

Conclusions:

• Manufacturers must navigate complex and heterogeneous reimbursement landscapes in the EU-5.
• A multi-faceted approach involving evidence generation, stakeholder engagement, and strategic pricing is essential for market access.
• Understanding the perceived value by payers is paramount for successful reimbursement negotiations.